Andreas Stallmach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5315917/publications.pdf

Version: 2024-02-01

126907 128289 4,036 102 33 60 citations g-index h-index papers 132 132 132 5508 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Expression of Interleukin-12-Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin-23p19 and Interleukin-27p28 in CrohnÊ $\frac{1}{4}$ s Disease But Not in Ulcerative Colitis. Inflammatory Bowel Diseases, 2005, 11, 16-23.	1.9	245
2	Drug delivery strategies in the therapy of inflammatory bowel disease. Advanced Drug Delivery Reviews, 2014, 71, 58-76.	13.7	196
3	Nano- and microscaled particles for drug targeting to inflamed intestinal mucosaâ€"A first in vivo study in human patients. Journal of Controlled Release, 2013, 165, 139-145.	9.9	183
4	Adverse effects of biologics used for treating IBD. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 167-182.	2.4	175
5	Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 1090-1102.	3.7	155
6	Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Alimentary Pharmacology and Therapeutics, 2016, 44, 1199-1212.	3.7	137
7	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of Hepatology, 2014, 60, 1249-1258.	3.7	113
8	Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 579-588.	1.9	108
9	Risk factors and outcome of bacterial infections in cirrhosis. World Journal of Gastroenterology, 2014, 20, 2542.	3.3	102
10	Consensus report: faecal microbiota transfer – clinical applications and procedures. Alimentary Pharmacology and Therapeutics, 2017, 45, 222-239.	3.7	95
11	Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut, 2000, 47, 415-422.	12.1	91
12	Increased state of activation of CD4 positive T cells and elevated interferon \hat{l}^3 production in pouchitis. Gut, 1998, 43, 499-505.	12.1	85
13	Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases—A Prospective Study on Incidence and Severity. Journal of Crohn's and Colitis, 2016, 10, 61-68.	1.3	81
14	Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series. Critical Care, 2020, 24, 444.	5.8	71
15	Classification of inflammatory bowel diseases by means of Raman spectroscopic imaging of epithelium cells. Journal of Biomedical Optics, 2012, 17, 0760301.	2.6	68
16	Inflammatory Bowel Disease in the COVID-19 Pandemic: the Patients' Perspective. Journal of Crohn's and Colitis, 2020, 14, 1702-1708.	1.3	67
17	Vedolizumab in the treatment of chronic, antibioticâ€dependent or refractory pouchitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 581-587.	3.7	64
18	Role of Infections in the Manifestation or Reactivation of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2002, 8, 213-218.	1.9	63

#	Article	IF	Citations
19	<i>NOD2</i> gene variants are a risk factor for cultureâ€positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver International, 2012, 32, 223-230.	3.9	59
20	Emergence of spontaneous bacterial peritonitis due to enterococci – risk factors and outcome in a 12â€year retrospective study. Alimentary Pharmacology and Therapeutics, 2012, 35, 1199-1208.	3.7	57
21	An interleukin 12 p40-lgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. Gut, 2004, 53, 339-345.	12.1	55
22	Discrimination and classification of liver cancer cells and proliferation states by Raman spectroscopic imaging. Analyst, The, 2014, 139, 6036-6043.	3.5	54
23	Medical and surgical therapy of inflammatory bowel disease in the elderly $\hat{a} \in \text{``Prospects}$ and complications. Journal of Crohn's and Colitis, 2011, 5, 177-188.	1.3	51
24	Treatment of refractory ascites with an automated lowâ€flow ascites pump in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2017, 46, 981-991.	3.7	46
25	Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterologica E Dietologica, 2005, 51, 127-45.	2.2	45
26	Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic. American Journal of Transplantation, 2020, 20, 3042-3050.	4.7	44
27	Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut, 2003, 52, 377-382.	12.1	38
28	T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 251-258.	1.3	37
29	The prognostic significance of bacterial <scp>DNA</scp> in patients with decompensated cirrhosis and suspected infection. Liver International, 2016, 36, 1133-1142.	3.9	36
30	Fecal Microbiota Transplant in Patients With Re current Clostridium Difficile Infection. Deutsches Ärzteblatt International, 2016, 113, 583-9.	0.9	35
31	Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PLoS ONE, 2017, 12, e0169900.	2.5	35
32	Comparison of fatigue, cognitive dysfunction and psychological disorders in post-COVID patients and patients after sepsis: is there a specific constellation?. Infection, 2022, 50, 661-669.	4.7	35
33	Biopsychosocial Determinants of Health-Related Quality of Life After Ileal Pouch Anal Anastomosis for Ulcerative Colitis*. Inflammatory Bowel Diseases, 2004, 10, 399-407.	1.9	29
34	Every slow-wave impulse is associated with motor activity of the human stomach. American Journal of Physiology - Renal Physiology, 2009, 296, G709-G716.	3.4	28
35	Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein–Barr virus infection under azathioprine. Inflammatory Bowel Diseases, 2009, 15, 1613-1616.	1.9	28
36	Towards an Interpretable Classifier for Characterization of Endoscopic Mayo Scores in Ulcerative Colitis Using Raman Spectroscopy. Analytical Chemistry, 2020, 92, 13776-13784.	6.5	27

#	Article	IF	CITATIONS
37	Activation of \hat{l}^21 integrins mediates proliferation and inhibits apoptosis of intestinal CD4-positive lymphocytes. European Journal of Immunology, 2001, 31, 1228-1238.	2.9	25
38	Magnetic Active Agent Release System (MAARS): Evaluation of a new way for a reproducible, externally controlled drug release into the small intestine. Journal of Controlled Release, 2012, 161, 722-727.	9.9	25
39	Pattern of mucosal adaptation in acute and chronic pouchitis. Diseases of the Colon and Rectum, 1999, 42, 1311-1317.	1.3	24
40	Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 661-677.	4.5	24
41	Classification and prediction of HCC tissues by Raman imaging with identification of fatty acids as potential lipid biomarkers. Journal of Cancer Research and Clinical Oncology, 2015, 141, 407-418.	2.5	23
42	Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 1028-1035.	1.9	22
43	An unmet medical need: Advances in endoscopic imaging of colorectal neoplasia. Journal of Biophotonics, 2011, 4, 482-489.	2.3	19
44	Parameters of a severe disease course in ulcerative colitis. World Journal of Gastroenterology, 2014, 20, 12574.	3.3	18
45	IgG, albumin, and sCD44 in whole-gut lavage fluid are useful clinical markers for assessing the presence and activity of pouchitis. International Journal of Colorectal Disease, 1999, 14, 35-40.	2.2	17
46	Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2859-2867.	1.8	17
47	SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Diseaseâ€"Fear and Desire. Inflammatory Bowel Diseases, 2021, 27, 1858-1861.	1.9	17
48	Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 21-28.	1.3	16
49	Long-term Multidonor Faecal Microbiota Transfer by Oral Capsules for Active Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1480-1481.	1.3	15
50	Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome. Gut, 2022, 71, 1567-1576.	12.1	15
51	Fecal Microbiota Transfer. Deutsches Ärzteblatt International, 2020, 117, 31-38.	0.9	15
52	Drug Monitoring in Inflammatory Bowel Disease: Helpful or Dispensable?. Digestive Diseases, 2009, 27, 394-403.	1.9	14
53	Esophageal Involvement in Cicatricial Pemphigoid. Endoscopy, 1998, 30, 657-661.	1.8	13
54	Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry. Journal of Crohn's and Colitis, 2018, 12, 695-701.	1.3	13

#	Article	IF	CITATIONS
55	Influence of Core Cross-Linking and Shell Composition of Polymeric Micelles on Immune Response and Their Interaction with Human Monocytes. Biomacromolecules, 2020, 21, 1393-1406.	5.4	13
56	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. JHEP Reports, 2021, 3, 100221.	4.9	12
57	Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region. Experimental and Molecular Pathology, 2003, 74, 262-266.	2.1	11
58	Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD. Gut, 2017, 66, 1531-1532.	12.1	11
59	Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis: A combined prospective-retrospective study. Scientific Reports, 2017, 7, 4914.	3.3	11
60	The COVID-19 Pandemic: Fears and Overprotection in Pediatric Patients with Inflammatory Bowel Disease and Their Families. Pediatric Gastroenterology, Hepatology and Nutrition, 2021, 24, 65.	1.2	10
61	Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years?. Journal of Crohn's and Colitis, 2015, 9, 390-397.	1.3	9
62	Immune response to autologous and heterologousHelicobacter pylori antigens in humans. Microscopy Research and Technique, 2001, 53, 419-424.	2.2	8
63	Increased expression of interleukin-12 receptor \hat{l}^22 on lamina propria mononuclear cells of patients with active Crohn's disease. International Journal of Colorectal Disease, 2002, 17, 303-310.	2.2	8
64	Malignant Transformation in Inflammatory Bowel Disease – Surveillance Guide. Digestive Diseases, 2009, 27, 584-590.	1.9	8
65	Motivation of patients with inflammatory bowel disease to participate in a clinical trial. Zeitschrift Fur Gastroenterologie, 2016, 54, 1123-1129.	0.5	8
66	Nondestructive molecular imaging by Raman spectroscopy <i>vs.</i> marker detection by MALDI IMS for an early diagnosis of HCC. Analyst, The, 2021, 146, 1239-1252.	3.5	8
67	Letter: SARS-CoV-2-induced gastrointestinal inflammation. Alimentary Pharmacology and Therapeutics, 2020, 52, 1748-1749.	3.7	8
68	Clinical characteristics and outcome of patients with enterococcal liver abscess. Scientific Reports, 2021, 11, 22265.	3.3	8
69	SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease. Zeitschrift Fur Gastroenterologie, 2022, 60, 77-80.	0.5	8
70	ROSâ€Sensitive Polymer Micelles for Selective Degradation in Primary Human Monocytes from Patients with Active IBD. Macromolecular Bioscience, 2022, 22, e2100482.	4.1	8
71	Interleukin-18 is increased only in a minority of patients with active Crohn's disease. International Journal of Colorectal Disease, 2007, 22, 1013-1020.	2.2	7
72	Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 165-175.	3.0	7

#	Article	IF	Citations
73	Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model. International Journal of Colorectal Disease, 2019, 34, 1653-1660.	2.2	7
74	Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines. Cells, 2020, 9, 79.	4.1	7
75	Detection of Liver Dysfunction Using a Wearable Electronic Nose System Based on Semiconductor Metal Oxide Sensors. Biosensors, 2022, 12, 70.	4.7	7
76	Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials, 2022, 23, 173.	1.6	7
77	Medical Therapy of Active Ulcerative Colitis. Visceral Medicine, 2015, 31, 236-245.	1.3	6
78	Effective use of ustekinumab for prepouch ileitis without improvement of concomitant pouchitis. Techniques in Coloproctology, 2018, 22, 251-252.	1.8	6
79	Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study. International Journal of Colorectal Disease, 2022, 37, 485-493.	2.2	6
80	Surveillance strategies in inflammatory bowel disease. Minerva Gastroenterologica E Dietologica, 2010, 56, 189-201.	2.2	6
81	Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals. Zeitschrift Fur Gastroenterologie, 2018, 56, 731-737.	0.5	4
82	Thumb sucking or nail biting in childhood and adolescence is associated with an increased risk of Crohn's disease: results from a large case–control study. Scandinavian Journal of Gastroenterology, 2020, 55, 1028-1034.	1.5	4
83	Mobile primary healthcare for post-COVID patients in rural areas: a proof-of-concept study. Infection, 2023, 51, 337-345.	4.7	4
84	Modulation of gastrointestinal inflammation by chimeric proteins in experimental models. Zeitschrift Fur Gastroenterologie, 2000, 38, 647-652.	0.5	3
85	Appendectomy in childhoodâ€"did it save my sibling from getting ulcerative colitis?. International Journal of Colorectal Disease, 2021, 36, 623-624.	2.2	3
86	The impact of specific cytokine directed treatment on severe COVID-19. Leukemia, 2021, 35, 3613-3615.	7.2	3
87	State of the Art: Therapeutical Strategies for the Treatment of Inflammatory Bowel Disease. Current Drug Therapy, 2013, 8, 99-120.	0.3	3
88	Acceptance of SARS-CoV-2 vaccines by liver transplant recipients and candidates. Zeitschrift Fur Gastroenterologie, 2021, 59, 1288-1296.	0.5	3
89	Letter: serum vitamin D levels in primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2015, 42, 633-634.	3.7	2
90	NOD2 Risk Variants and Pathological Bacterial Translocation in Decompensated Cirrhosis. Digestive Diseases and Sciences, 2016, 61, 2142-2144.	2.3	2

#	Article	IF	CITATIONS
91	Letter: predicting azathioprineâ€associated pancreatitis in <scp>IBD</scp> â€"phenotype or genotype?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1042-1043.	3.7	2
92	Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?. American Journal of Gastroenterology, 2021, 116, 1964-1965.	0.4	2
93	Azathioprine allows glucocorticoid withdrawal – post hoc results of a prospective study in patients with inflammatory bowel diseases. Zeitschrift Fur Gastroenterologie, 2017, 55, 461-465.	0.5	1
94	Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series. Inflammatory Intestinal Diseases, 2017, 2, 139-146.	1.9	1
95	Role of T Cells in Mucosal Transformation of Ileoanal Pouches. Annals of the New York Academy of Sciences, 1998, 859, 231-236.	3.8	0
96	Serum metabolic signatures in patients with overt hepatic encephalopathy. Journal of Hepatology, 2017, 67, 1114-1115.	3.7	0
97	Development of an advanced diagnostic concept for intestinal inflammation: molecular visualisation of nitric oxide in macrophages by functional poly(lactic-co-glycolic acid) microspheres. Beilstein Journal of Nanotechnology, 2017, 8, 1637-1641.	2.8	0
98	Morbus Crohn. , 2021, , 234-247.		0
99	Morbus Crohn. , 2015, , 1-12.		0
100	Morbus Crohn. , 2018, , 361-372.		0
101	Hepatitis E is a frequent cause of severe acute liver injury – a tertiary referral center experience. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
102	Morbus Crohn. , 2019, , 196-208.		0